# Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

> **NCT01328535** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 25 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **DRUG:** temozolomide
- **OTHER:** flow cytometry
- **OTHER:** staining method
- **PROCEDURE:** biopsy
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01328535
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-06-22
- **Final completion:** 2018-07-11
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01328535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01328535, "Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01328535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*